Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
These initiatives were driven by Baroness Brinton, and are more likely to reflect personal policy preferences.
MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.
Baroness Brinton has not been granted any Urgent Questions
Baroness Brinton has not been granted any Adjournment Debates
Baroness Brinton has not co-sponsored any Bills in the current parliamentary sitting
The success of the COVID-19 vaccination programme has meant that shielding and identifying people as clinically extremely vulnerable (CEV) are no longer necessary. This is because the majority of those previously considered to be CEV will benefit from the COVID-19 vaccine. However, there remains a smaller number of people who, in spite of vaccination, are at higher risk of serious illness from COVID-19. This is due to a weakened immune system or specific other medical condition, which means they require enhanced protections such as those offered by antivirals and therapeutics, additional vaccinations and potentially other non-clinical interventions.
Within this smaller group, approximately 1.3 million people have been identified as potentially eligible for Antivirals, and Neutralising Monoclonal Antibodies, as non-hospitalised treatments, and approximately 0.5 million people in England have been identified as severely immunosuppressed and therefore eligible for a third primary COVID-19 vaccine dose.
The information requested is not centrally collected.
We have signed contracts to supply over 10 million tests from Roche and Abbott in the coming months. We have agreed these contracts with two suppliers whose assays have been evaluated by Public Health England and continue to engage with other companies to establish further agreements to meet our testing strategy. These contracts will secure a significant volume to meet the United Kingdom’s testing plans. Further details are commercially sensitive.
Public Health England (PHE) were asked to review all major suppliers of assays for National Health Service use, including the Roche Elecsys Anti-SARS-CoV-2 antibody test, in order to limit the amount of on-site evaluation each facility has to perform.
PHE is familiar with the processes involved in European Medicine Agency registration. No discussions have been held with stakeholders in Germany about their trial and approvals processes.